Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - mark greene

6 Results Sort By:
TIP60 inhibitors – therapy for Irritable Bowel Disease (IBD); ulcerative colitis and Crohn’s diseases
Inhibitors of TIP60, maintaining regulatory T cells (Tregs) and ameliorating autoimmune diseases. ProblemInflammatory bowel disease (IBD) involves chronic inflammation of all or part of digestive tract. IBD includes ulcerative colitis and Crohn’s disease both very prevalent and known to cause severe complications and discomfort. Inhibitors of...
Published: 12/4/2018   |   Inventor(s): Mark Greene
Keywords(s): Biotechnology
Category(s): Therapeutics & Vaccines
ANTIBODY-LIKE THERAPEUTIC PLATFORM WITH EFFECTOR FUNCTION
While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibodies require post-translational modifications and must be produced in ...
Published: 1/31/2018   |   Inventor(s): Mark Greene
Keywords(s): Antibody, Therapeutics
Category(s): Therapeutics & Vaccines
A method to identify modulators for regulatory T cell functions
Docket # T4518 Technology OverviewMaintenance of tolerance to self-antigens is essential for the prevention of autoimmunity. This process is known to involve specific regulatory T cells (Treg) and the expression of the forkhead family transcription factor, FOXP3. FOXP3 is a “sufficient” regulator of the development and function of peri...
Published: 8/10/2017   |   Inventor(s): Mark Greene
Keywords(s): Autoimmune, Biotechnology
Category(s): Research Tools & Reagents
Diagnosis and treatment of prostate cancer using a prostate cancer antibody
Brief DescriptionMonoclonal antibody and immunotherapy use in prostate cancer Docket # V5084 Technology OverviewBoth androgen dependent and independent prostatic carcinomas have a high potential to metastasize; unfortunately, the overall 5-year survival rate for metastatic prostate cancer is only 34%. Dr. Greene and his collaborators at the Unive...
Published: 6/10/2015   |   Inventor(s): Mark Greene
Keywords(s): Cancer
Category(s): Diagnostics, Therapeutics & Vaccines
Therapy for heparin-induced thrombocytopenia (HIT) targeting the epitope structure of the disease –inducing antibody
Technology OverviewRoughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis and thrombocytopenia. The Greene lab has identified...
Published: 5/20/2015   |   Inventor(s): Mark Greene
Keywords(s): Antibody, Reagents: Antibodies
Category(s): Diagnostics, Therapeutics & Vaccines, Research Tools & Reagents
Her2/Neu Inhibitors for Cancer Therapy and Molecular Imaging
Cancer affects approximately 10 million people globally, with breast and lung cancer accounting for 25% of cancer incidences.Assuming over expression of Her2 is responsible for 25% of the breast cancer and lung cancer, and then the estimated market is about one million. The estimated price of Lapatinib, a small molecule tyrosine kinase inhibitor, i...
Published: 5/20/2015   |   Inventor(s): Mark Greene
Keywords(s): Biotechnology, Cancer
Category(s): Therapeutics & Vaccines, Imaging